PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma (iPREFER)

May 5, 2026 updated by: The Christie NHS Foundation Trust
This is a qualitative (interview) study to explore the experiences of people receiving treatment for MM and to understand what matters most to participants when making treatment decisions.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

People can receive many lines of treatment for multiple myeloma. The investigators would like to understand more about the experiences of people being treated for multiple myeloma including what matters most to participants when considering treatment options, how participants experiences have differed with different treatments and if participants have any treatment preferences. Patients at The Christie who have received five or more lines of treatment for Multiple Myeloma will be eligible to take part in this study. Participants will be asked to take part in an interview which should take approximately 30 minutes to an hour. During the interview, participants will be asked questions regarding their experiences and preference for treatment. Interviews will be conducted either in person or over the phone depending on patient preference. The interviews will be recorded by the research team using a Dictaphone and transcribed by an external transcription service called 1st Class Secretarial. The transcripts of all participant interviews will be reviewed by members of the research team and experiences will be identified and described.

Study Type

Observational

Enrollment (Actual)

9

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United Kingdom
    • Greater Manchester
      • Manchester, Greater Manchester, United Kingdom, M20 4BX
        • The Christie NHS Foundation Trust

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with multiple myeloma who have received at least five lines of treatment.

Description

Inclusion Criteria:

  1. Participants with confirmed MM (per standard disease specific diagnostic criteria)

  2. Participants must have received ≥ 5 lines of treatment for MM and fit into one of the below treatment categories:

    1. Subset 1- Participants must have received an oral anti-cancer therapy and a bi-specific antibody treatment.
    2. Subset 2- Participants must have received an oral anti-cancer therapy and if they have not had a bi-specific antibody treatment, they must have received at least one IV therapy.
  3. Aged 18 years of age or over
  4. Able to provide informed consent
  5. Able to communicate in English

Exclusion Criteria:

  1. Aged under 18
  2. Unable to understand and communicate in the English language
  3. Unable to provide written informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patient Interviews
Participants will be asked to take part in a 30-60 minute interview to understand their treatment preferences. Members of the research team will conduct this either in the clinic or over the phone, as per patient preference.
Other: Patient Interview
Participants will be asked to take part in a 30-60 minute interview to understand their treatment experiences and preferences.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient Experience and Preference
Time Frame: 30-60 minutes
The interview will explore the experiences of people receiving treatment for multiple myeloma and understand what matters most to them when making treatment decisions.
30-60 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Treatment and Preference Differences
Time Frame: 30-60 minutes
The interview will explore how experiences have differed across different lines of treatment and determine if people with multiple myeloma have any preferences for particular treatments.
30-60 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The Christie NHS Foundation Trust

Collaborators

CellCentric Ltd.

Investigators

  • Principal Investigator: Sally Taylor, PhD, The Christie NHS Foundation Trust

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 5, 2024

Primary Completion (Actual)

September 30, 2024

Study Completion (Actual)

September 30, 2024

Study Registration Dates

First Submitted

March 14, 2024

First Submitted That Met QC Criteria

March 14, 2024

First Posted (Actual)

March 21, 2024

Study Record Updates

Last Update Posted (Actual)

May 8, 2026

Last Update Submitted That Met QC Criteria

May 5, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CFTsp231
  • 24_CPCR_38 (Other Identifier: ChristieNHS)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Myeloma

Clinical Trials on Patient Interview

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe